BCM
CLYM

Bluefin Capital Management’s Climb Bio CLYM Stock Holding History

Bluefin Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-59,985
Closed -$121K – 215
2025
Q3 		$121K Buy
+59,985
New +$111K 0.04% 56

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bluefin Capital Management's CLYM Position: Q4 2025 in Review

Bluefin Capital Management sold out of Climb Bio (CLYM) in Q4 2025, closing a stake of 59,985 shares — an estimated $121K sold.

Bluefin Capital Management first reported a position in CLYM in Q3 2025 and held it in 1 quarter. The position peaked at $121K in Q3 2025. 65 funds tracked by Wall St. Rank hold CLYM as of Q4 2025.

  • Bluefin Capital Management reported no remaining Climb Bio position as of Q4 2025 after selling out during the quarter.
  • Bluefin Capital Management sold 59,985 Climb Bio shares in Q4 2025, an estimated $121K.
  • Bluefin Capital Management first reported a position in Climb Bio in Q3 2025 and held it in 1 quarter.
  • Bluefin Capital Management's Climb Bio position peaked at $121K in Q3 2025.
  • 65 funds tracked by Wall St. Rank held Climb Bio as of Q4 2025.

Based on Bluefin Capital Management's 13F filing for Q4 2025, filed 29 Apr 2026.